Q-omics provides the consensus-scored RPL32P19 profile across patient tissues and cancer cell-line models. RPL32P19 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RPL32P19 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, RPL32P19 RNA expression shows 4,209 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, and STAD as cancer lineages where RPL32P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL32P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL32P19 survival associations across molecular data types. RPL32P19 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL32P19 RNA expression–survival associations across cancer types. High RPL32P19 expression shows unfavorable associations in PAAD, CESC, DLBC, LUSC and TGCT, but favorable associations in LIHC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for RPL32P19 RNA expression.
This table summarizes RPL32P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL32P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL32P19 shows lower tumor expression in STAD and higher tumor expression in THCA. The STAD box plot shows higher RPL32P19 RNA expression in normal versus tumor tissue (log2 FC = −0.046, t-test p = .009).
This table shows molecular features associated with RPL32P19 in patient tissues and cancer cell lines. In patient samples, RPL32P19 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
